Natera, Inc. (NTRA) Stock Score, Valuation & Financial Research
Natera, Inc. is in the Healthcare sector and Medical - Diagnostics & Research industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 36/100.
Quick answer for NTRA
Natera, Inc. currently has a Wall Street Score of 36/100. The stored market price is $336.59. Its financial score is 32/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Natera, Inc. does
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity durin
NTRA financial snapshot
- Wall Street Score:
- 36/100
- Current price:
- $336.59
- Market capitalization:
- $48.20B
- Revenue:
- $2.50B
- Net income:
- $-226.3M
- Free cash flow:
- $109.1M
- Cash:
- $1.09B
- Total debt:
- $240.1M
- EPS:
- -1.52
- Financial score:
- 32/100
- Valuation score:
- 0/100
- Revenue score:
- 29/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $109.1M, showing positive cash generation.
- The balance sheet shows $1.09B of cash versus $240.1M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 32/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research NTRA
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.